Figure 5 Multi-omics study to investigate the clinical value of hypoxia-stemness risk classifier(A) Correlation of patient risk score with immune infiltration based on xCell algorithm. (B) CD8 expression in high- and low-risk groups. (C) CD274 (PD-L1) expression in high-risk and low-risk patients. (D–I) Comparison of common chemotherapeutic agents’ sensitivity in high- and low-risk groups of ESCA patients, including Metformin (D), Mitomycin (E), Gefitinib (F), Bexarotene (G), Dasatinib. (H), and Imatinib (I). The significance was assessed by the Wilcoxon test. (J) Mutation mapping of ESCA patients between high and low-risk esophageal cancer patients, genes with the top 30 mutation frequencies were represented.